TY - JOUR
T1 - Synthesis of propargylamine mycophenolate analogues and their selective cytotoxic activity towards neuroblastoma SH-SY5Y cell line
AU - Silalai, Patamawadee
AU - Pruksakorn, Dumnoensun
AU - Chairoungdua, Arthit
AU - Suksen, Kanoknetr
AU - Saeeng, Rungnapha
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Twenty six propargylamine mycophenolate analogues were designed and synthesized from mycophenolic acid 1 employing a key step A3-coupling reaction. Their cytotoxic activity was examined against six cancer cell lines. Compounds 6a, 6j, 6t, 6u, and 6z exhibited selective cytotoxicity towards neuroblastoma (SH-SY5Y) cancer cells and were less toxic to normal cells in comparison to the lead compound, MPA 1 and a standard drug, ellipticine. Molecular docking results suggested that compound 6a is fit well in the key amino acid of three proteins (CDK9, EGFR, and VEGFR-2) as targets in cancer therapy. The propargylamine mycophenolate scaffold might be a valuable starting point for development of new neuroblastoma anticancer drugs.
AB - Twenty six propargylamine mycophenolate analogues were designed and synthesized from mycophenolic acid 1 employing a key step A3-coupling reaction. Their cytotoxic activity was examined against six cancer cell lines. Compounds 6a, 6j, 6t, 6u, and 6z exhibited selective cytotoxicity towards neuroblastoma (SH-SY5Y) cancer cells and were less toxic to normal cells in comparison to the lead compound, MPA 1 and a standard drug, ellipticine. Molecular docking results suggested that compound 6a is fit well in the key amino acid of three proteins (CDK9, EGFR, and VEGFR-2) as targets in cancer therapy. The propargylamine mycophenolate scaffold might be a valuable starting point for development of new neuroblastoma anticancer drugs.
KW - A-coupling reaction
KW - Cytotoxic activity
KW - Molecular docking
KW - Mycophenolic Acid
KW - Neuroblastoma SH-SY5Y cells
KW - Propargylamine mycophenolate
UR - http://www.scopus.com/inward/record.url?scp=85107125312&partnerID=8YFLogxK
U2 - 10.1016/j.bmcl.2021.128135
DO - 10.1016/j.bmcl.2021.128135
M3 - Article
C2 - 34044119
AN - SCOPUS:85107125312
SN - 0960-894X
VL - 45
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
M1 - 128135
ER -